Skip to Content

Cytarabine liposomal / daunorubicin liposomal Disease Interactions

There are 6 disease interactions with cytarabine liposomal / daunorubicin liposomal:

Major

Antineoplastics (applies to cytarabine liposomal/daunorubicin liposomal) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  3. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  4. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  5. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  6. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  8. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  9. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  10. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  11. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  12. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  13. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  14. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  15. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  16. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  17. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  18. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  19. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL.
  20. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  21. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  22. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  23. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
  24. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  25. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  26. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  27. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  28. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  29. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  30. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  31. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
View all 31 references
Major

Cytarabine (applies to cytarabine liposomal/daunorubicin liposomal) meningeal infection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.

Major

Cytarabine (applies to cytarabine liposomal/daunorubicin liposomal) myelosuppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Fever, Bleeding, Bone Marrow Depression/Low Blood Counts

Cytarabine is a potent bone marrow suppressant. Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily. Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood. Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.

References

  1. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Daunorubicin (applies to cytarabine liposomal/daunorubicin liposomal) congestive heart failure

Major Potential Hazard, Moderate plausibility.

Daunorubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment. The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2. An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.

References

  1. Ferrans VJ "Overview of cardiac pathology in relation to anthracycline cardiotoxicity." Cancer Treat Rep 62 (1978): 955-61
  2. Al-Ismail SA, Parry DH, Whittaker JA "Anthracycline cardiotoxicity and acute myelogenous leukaemia." Br Med J 1 (1977): 815
  3. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM "Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases." Am J Med 62 (1977): 200-8
  4. Harrison DT, Sanders LA "Letter: Pericarditis in a case of early daunorubicin cardiomyopathy." Ann Intern Med 85 (1976): 339-41
  5. Ainger LE, Bushore J, Johnson WW, Ito J "Daunomycin: a cardiotoxic agent." J Natl Med Assoc 63 (1971): 261-7
  6. Malhotra OP, Talwar KK, Chopra P, Kumar R "Erythroleukaemia and daunorubicin-induced cardiotoxicity in a young boy." Br J Clin Pract 44 (1990): 633-4
  7. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES "Cardiac ultrastructural changes induced by daunorubicin therapy." Cancer 32 (1973): 771-88
  8. Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E "Anthracycline induced myocardial damage. An analysis of 16 autopsy cases." Pathol Res Pract 181 (1986): 434-41
  9. Von Hoff DD, Layard M "Risk factors for development of daunorubicin cardiotoxicity." Cancer Treat Rep 65 Suppl 4 (1981): 19-23
  10. "Daunorubicin and the heart." Br Med J 4 (1974): 431-2
  11. Mhatre R, Herman E, Huidobro A, Waravdekar V "The possible relationship between metabolism and cardiac toxicity of duanomycin and related compounds." J Pharmacol Exp Ther 178 (1971): 216-22
View all 11 references
Major

Daunorubicin (applies to cytarabine liposomal/daunorubicin liposomal) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Daunorubicin can induce severe myelosuppression at therapeutic doses. The use of daunorubicin may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.
  2. "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Daunorubicin liposomal (applies to cytarabine liposomal/daunorubicin liposomal) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bleeding, Bone Marrow Depression/Low Blood Counts, Fever

Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting-existing drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage.

References

  1. "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.

Cytarabine liposomal / daunorubicin liposomal drug interactions

There are 428 drug interactions with cytarabine liposomal / daunorubicin liposomal

More about cytarabine liposomal / daunorubicin liposomal

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.